|
|
Article: ImClone's Phase III Erbitux Trial In NSCLC Fails To Hit Endpoint.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
ImClone Systems Inc.'s Phase III miss with Erbitux (cetuximab) in non-small-cell lung cancer might have been due to a mid-trial protocol switch and wasn't a pivotal study anyway, but the failure could give a perceptual edge to Avastin (bevacizumab), Genentech Inc.'s VEGF inhibitor.
Shares of ImClone (NASDAQ:IMCL) dipped on the news, closing Thursday at $34.73, down $1.17. Genentech's stock (NYSE:DNA) ended the day down 56 cents, closing at $75.37. Despite strong second-quarter results, some Genentech analysts worried that sales might be flattening out.
New York-based ImClone and partner Bristol-Myers Squibb Co., also of New ...